Shares of ResMed Inc. RMD advanced 3.29% to $232.44 Friday, on what proved to be an all-around positive trading session for ...

A new survey finds that 33% of Singaporeans suffer from poor sleep—affecting productivity, relationships, and well-being.

ResMed RMD has achieved impressive growth over the past year, with its shares rallying 25.6%. It has outperformed the industry’s 13.1% rise and the S&P 500 composite’s 15.7% gain. Presently carrying a ...

ResMed Inc. (NYSE:RMD – Get Free Report)’s stock price traded down 4.3% during mid-day trading on Wednesday after an insider sold shares in the company.The stock traded as low as $221.34 and ...

ResMed Inc.’s RMD growth in the second quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth. The company’s ...

The buy ratings keep piling in for ResMed. The post Citi slaps buy rating on ResMed shares appeared first on The Motley Fool ...

This was the stock's third consecutive day of losses.

SINGAPORE: A recent study has shed light on the widespread sleep issues plaguing Singapore, with a concerning number of ...

Highlights,Hedge funds and financial firms have adjusted their positions in ResMed, reflecting institutional activity.,The ...

Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...

ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short ...

Citi upgraded ResMed (RMD) to Buy from Neutral with a price target of A$44, up from A$41. The firm likes the stock’s “reasonable valuation, ...